Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects

Registry ID

EUCTR2016-001878-15

Source registry

EUCTR

Phase

PHASE1

Sponsor

Eisai Medical Research Inc.

Last update

2026-08-16

Conditions

• Gastroesophageal Reflux Disease (GERD)

Summary

To characterize the PK profile of single and repeated doses of rabeprazole sodium in subjects 12 to 16 years of age with a diagnosis of, or symptoms of, GERD.

Related clinical trials

• Indiana University Gastrointestinal Motility Diagnosis Registry
• Esophageal Cancer Risk Registry
• Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
• Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
• Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease

View on source registry